These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

121 related items for PubMed ID: 15301246

  • 1. Renal function in rheumatoid arthritis patients treated with methotrexate and infliximab.
    Wiland P, Wiela-Hojenska A, Glowska A, Chlebicki A, Hurkacz M, Orzechowska-Juzwenko K, Szechinski J.
    Clin Exp Rheumatol; 2004; 22(4):469-72. PubMed ID: 15301246
    [Abstract] [Full Text] [Related]

  • 2. [Renal tubular dysfunction in patients with rheumatoid arthritis starting with low dose of methotrexate].
    Wiland P, Wiela-Hojeńska A, Swierkot J, Hurkacz M, Orzechowska-Juzwenko K, Szechiński J.
    Pol Arch Med Wewn; 2003 Aug; 110(2):855-62. PubMed ID: 14682224
    [Abstract] [Full Text] [Related]

  • 3. N-acetyl-beta-D-glucosaminidase urinary excretion as an early indicator of kidney dysfunction in rheumatoid arthritis patients on low-dose methotrexate treatment.
    Wiland P, Swierkot J, Szechiński J.
    Br J Rheumatol; 1997 Jan; 36(1):59-63. PubMed ID: 9117176
    [Abstract] [Full Text] [Related]

  • 4. N-acetyl-beta-D-glucosaminidase urinary excretion as an early indicator of kidney damage in rheumatoid arthritis patients starting on parenteral gold and Depo-Medrone/placebo injections.
    Wiland P, Szechiński J.
    Clin Rheumatol; 1999 Jan; 18(2):106-13. PubMed ID: 10357114
    [Abstract] [Full Text] [Related]

  • 5. Aiming at low disease activity in rheumatoid arthritis with initial combination therapy or initial monotherapy strategies: the BeSt study.
    Allaart CF, Goekoop-Ruiterman YP, de Vries-Bouwstra JK, Breedveld FC, Dijkmans BA, FARR study group.
    Clin Exp Rheumatol; 2006 Jan; 24(6 Suppl 43):S-77-82. PubMed ID: 17083767
    [Abstract] [Full Text] [Related]

  • 6. Open label study to assess infliximab safety and timing of onset of clinical benefit among patients with rheumatoid arthritis.
    Shergy WJ, Isern RA, Cooley DA, Harshbarger JL, Huffstutter JE, Hughes GM, Spencer-Smith EA, Goldman AL, Roth SH, Toder JS, Warner D, Quinn A, Keenan GF, Schaible TF, PROMPT Study Group. Profiling Remicade Onset with MTX in a Prospective Trial.
    J Rheumatol; 2002 Apr; 29(4):667-77. PubMed ID: 11950005
    [Abstract] [Full Text] [Related]

  • 7. N-acetyl-beta-D-glucosaminidase enzymuria as an indicator in monitoring the therapy of some rheumatic diseases with potentially nephrotoxic drugs.
    Wiland P, Szechiński J.
    Arch Immunol Ther Exp (Warsz); 1994 Apr; 42(4):331-6. PubMed ID: 7487376
    [Abstract] [Full Text] [Related]

  • 8. Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group.
    Lipsky PE, van der Heijde DM, St Clair EW, Furst DE, Breedveld FC, Kalden JR, Smolen JS, Weisman M, Emery P, Feldmann M, Harriman GR, Maini RN, Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group.
    N Engl J Med; 2000 Nov 30; 343(22):1594-602. PubMed ID: 11096166
    [Abstract] [Full Text] [Related]

  • 9. Evidence of radiographic benefit of treatment with infliximab plus methotrexate in rheumatoid arthritis patients who had no clinical improvement: a detailed subanalysis of data from the anti-tumor necrosis factor trial in rheumatoid arthritis with concomitant therapy study.
    Smolen JS, Han C, Bala M, Maini RN, Kalden JR, van der Heijde D, Breedveld FC, Furst DE, Lipsky PE, ATTRACT Study Group.
    Arthritis Rheum; 2005 Apr 30; 52(4):1020-30. PubMed ID: 15818697
    [Abstract] [Full Text] [Related]

  • 10. Methotrexate dosage reduction in patients with rheumatoid arthritis beginning therapy with infliximab: the Infliximab Rheumatoid Arthritis Methotrexate Tapering (iRAMT) trial.
    Fleischmann RM, Cohen SB, Moreland LW, Schiff M, Mease PJ, Smith DB, Keenan G, Kremer JM, iRAMT Study Group.
    Curr Med Res Opin; 2005 Aug 30; 21(8):1181-90. PubMed ID: 16083527
    [Abstract] [Full Text] [Related]

  • 11. Combination of infliximab and methotrexate therapy for early rheumatoid arthritis: a randomized, controlled trial.
    St Clair EW, van der Heijde DM, Smolen JS, Maini RN, Bathon JM, Emery P, Keystone E, Schiff M, Kalden JR, Wang B, Dewoody K, Weiss R, Baker D, Active-Controlled Study of Patients Receiving Infliximab for the Treatment of Rheumatoid Arthritis of Early Onset Study Group.
    Arthritis Rheum; 2004 Nov 30; 50(11):3432-43. PubMed ID: 15529377
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Very early treatment with infliximab in addition to methotrexate in early, poor-prognosis rheumatoid arthritis reduces magnetic resonance imaging evidence of synovitis and damage, with sustained benefit after infliximab withdrawal: results from a twelve-month randomized, double-blind, placebo-controlled trial.
    Quinn MA, Conaghan PG, O'Connor PJ, Karim Z, Greenstein A, Brown A, Brown C, Fraser A, Jarret S, Emery P.
    Arthritis Rheum; 2005 Jan 30; 52(1):27-35. PubMed ID: 15641102
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Proximal tubule damage in patients treated with gentamicin or amikacin.
    Wiland P, Szechciński J.
    Pol J Pharmacol; 2003 Jan 30; 55(4):631-7. PubMed ID: 14581723
    [Abstract] [Full Text] [Related]

  • 17. Discontinuation of infliximab and potential predictors of persistent low disease activity in patients with early rheumatoid arthritis and disease activity score-steered therapy: subanalysis of the BeSt study.
    van den Broek M, Klarenbeek NB, Dirven L, van Schaardenburg D, Hulsmans HM, Kerstens PJ, Huizinga TW, Dijkmans BA, Allaart CF.
    Ann Rheum Dis; 2011 Aug 30; 70(8):1389-94. PubMed ID: 21515916
    [Abstract] [Full Text] [Related]

  • 18. Early rheumatoid arthritis in a patient with Sjögren's syndrome and pulmonary nodular amyloidosis: clinical implication of early limited use of infliximab.
    Mori S, Koga Y, Imamura F, Cho I, Sugimoto M.
    Mod Rheumatol; 2007 Aug 30; 17(6):500-6. PubMed ID: 18084704
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Autoantibodies, metalloproteinases and bone markers in rheumatoid arthritis patients are unable to predict their responses to infliximab.
    Lequerré T, Jouen F, Brazier M, Clayssens S, Klemmer N, Ménard JF, Mejjad O, Daragon A, Tron F, Le Loët X, Vittecoq O.
    Rheumatology (Oxford); 2007 Mar 30; 46(3):446-53. PubMed ID: 16899502
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.